SureTrader Advertisement PRTC
Home > Boards > Free Zone > Health and Sciences > Biotech Values

The estimated patent date of Remicade and Rituxan

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (3) | Next 10 | Previous | Next
rwdm Member Profile
 
Followed By 3
Posts 103
Boards Moderated 0
Alias Born 07/19/10
160x600 placeholder
Stocks End Little Changed As Oil Rally Runs Out Of Steam
Pending home sales surge in April U.S. stocks closed little changed Thursday after two days of strong gains as crude-oil futures failed to...
Top Equities Stories Of The Day
Wells Fargo to Offer Low-Down-Payment Mortgages Without FHA Backing
LendingClub Talking With Citigroup About Loan Purchases
Correction to Microsoft Smartphone Article on Wednesday
Facebook and Microsoft To Build Fiber Optic Cable Across Atlantic
Snapchat Valuation Nears $18 Billion
India to Require Apple to Use Local Sourcing
GE to Supply Engines for South Korea's New Fighters
Wells Fargo to Offer Low-Down-Payment Mortgages Without FHA Backing
rwdm   Thursday, 07/29/10 02:07:10 PM
Re: None
Post # of 201620 
The estimated patent date of Remicade and Rituxan in Europe are 2014 and 2015 respectively. In the US both expiry dates are in 2018. Is this because of Genentech's Cabily patent? If yes, does this mean that the expiry date of most of the mabs in US is 2018?

Is Teva's Rituximab TL011, which is starting nowadays clinical trials, in the regulatory pathway of BLA or as a biosimilar?

SureTrader
Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (3) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist